Home
About
Overview
Sharing Data
ORCID
Help
History (1)
A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.
A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients. Expert Opin Drug Saf. 2015 Mar; 14(3):485-93.
View in:
PubMed
subject areas
Animals
Antineoplastic Agents
Carcinoma, Non-Small-Cell Lung
Drug Interactions
Humans
Lung Neoplasms
Mutation
Protein Kinase Inhibitors
Pyrazoles
Pyridines
Quality of Life
Receptor Protein-Tyrosine Kinases
authors with profiles
Ravi Salgia